
The US Food and Drug Administration granted emergency use authorization of intravenous neuraminidase inhibitors for patients with 2009 influenza A (H1N1), creating a need for economic studies.
The US Food and Drug Administration granted emergency use authorization of intravenous neuraminidase inhibitors for patients with 2009 influenza A (H1N1), creating a need for economic studies.
The US Food and Drug Administration granted emergency use authorization of intravenous neuraminidase inhibitors for patients with 2009 influenza A (H1N1), creating a need for economic studies.
Vaccinating children earlier (ie, September or October) can provide net economic benefit to society and to third-party payers. Vaccination of children remained cost-effective through December.
Published: March 10th 2011 | Updated:
Published: January 14th 2011 | Updated:
Published: March 1st 2010 | Updated:
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.